Sense Biodetection Limited
Registered name: SENSE BIODETECTION LIMITED
Sense Biodetection Limited made £5.8m revenue and a £380k loss in the year to 31 Dec 2025. read from filing text
Sense Biodetection Limited’s revenue was £5.8m in the year to 31 Dec 2025, with a loss of £380k and 24 employees. The company is classified under “research and experimental development on biotechnology” and is based in Abingdon; we hold 2 years of its filed accounts.
- Status
- Active
- Location
- Abingdon, South East
- Age
- 13 yrs · since 2013
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “T”
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2024 | 31 Dec 2025 |
|---|---|---|
| Disclosure | Full P&Lread from filing text | Full P&Lread from filing text |
| Profit & loss | ||
| Revenue (turnover) | £0 | £5.8m |
| Gross profit | £0 | £5.8m |
| Operating profit | £188k | −£242k |
| Profit before tax | −£278k | −£380k |
| Profit (best available) | −£278k | −£380k |
| Staff costs | £1.9m | £1.6m |
| Employees (average) | 30 | 24 |
| Ratios | ||
| Profit margin | — | −6.5% |
| Gross margin | — | 100% |
| Revenue per employee | £0 | £243k |
| Profit per employee | −£9.3k | −£15.8k |
| Growth (year on year) | ||
| Headcount growth | — | ▼20% |
| Balance sheet — indirect signals, not revenue | ||
| Cash at bank | £293k | £100k |
| Net assets | −£14.2m | −£12.7m |
| Source | FullAccounts · bulk data Aug 2026 | FullAccounts · bulk data Aug 2026 |
How the business works
- Profit margin
- −6.5%
- Profit ÷ revenue.
- Gross margin
- 100%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £243k
- Revenue ÷ average employees.
- Profit per employee
- −£15.8k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- —
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now −£12.7m
- Cash at bank
- ▼66%
- Now £100k
- Headcount
- ▼20%
- Now 24
- Deferred income
- —
- Now —
- Fixed assets
- —
- Now —
Similar profitable businesses
- Clinuvel (UK) LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £6.4m
- Profit
- £81.6k
- Staff
- 46
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
- Flatiron Health UK LtdST Albans · Research and experimental development on biotechnology
- Revenue
- £9.5m
- Profit
- £239k
- Staff
- 32
- Biopharma Process Systems LimitedWinchester · Research and experimental development on biotechnology
- Revenue
- £10.1m
- Profit
- £142k
- Staff
- 66
- Takara Bio UK LtdLondon · Research and experimental development on biotechnology
- Revenue
- £3.1m
- Profit
- £97.2k
- Staff
- 9
- Askbio UK LtdMidlothian · Research and experimental development on biotechnology
- Revenue
- £12.5m
- Profit
- £1.8m
- Staff
- 54
Sources
Latest figures from FullAccounts for the year to 31 Dec 2025 (profit −£380k), from the Companies House accounts bulk data published Aug 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.